Duchenne Muscular Dystrophy Testing Market -Low-down on Duchenne Muscular Dystrophy Testing

Duchenne Muscular Dystrophy (DMD) is an autoimmune, inherited disorder found mostly in male children that leads to abnormality in walking, difficulty in standing and muscle weakness, and is fatal in almost all cases. However, a female child can also be affected. The global prevalence of Duchenne muscular dystrophy is estimated to be 1 male for 3,500 live male births and is most common in the age group of 1-6 years. Early testing strategies can quickly diagnose this condition and help initiate treatment at an early stage, to slacken the progress of the disease.

Get Sample Copy of this Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6495

Testing for DMD:

  • Plasma creatine phospho kinase tests – Measuring the Creatine phospho kinase(CPK)  enzyme levels quickly and assuredly assists in the diagnosis of DMD
  • Muscle biopsy- A more tedious yet more accurate way of diagnosing DMD is a muscle biopsy performed on any muscle of the concerned child (usually the calf muscle), followed by a microscopic analysis of the same
  • Genetic testing- A prophylactic solution to this disease, genetic testing can warn parents beforehand of their risk of bearing children with this disease.
  • Electromyography testing (EMG)- EMG testing is used to assess muscle function and serviceability, and is used throughout this disease to assess residual muscle function.

Check Table of Contents of this Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6495

Regional Analysis of Market:

With an increasing incidence of autoimmune conditions and a well established health infrastructure in the United States and Europe, these areas are set to witness growth in the market for Duchenne Muscular Dystrophy testing. Muscular dystrophy testing can range from about USD 100 to more than USD 2,000, depending on type and complexity of tests as described above, hence this market will duly grow in developed nations where healthcare infrastructure is developed, awareness levels are high, and disposable incomes are high. Asia Pacific will create new growth opportunities owing to growing awareness and increasing government efforts towards better outcomes.

Awareness about Early Diagnosis to Propel Growth of Duchenne Muscular Dystrophy Testing Market

The Duchenne muscular dystrophy testing market expects a surge in the growth rate across the forecast period of 2019-2029 mainly due to the rising awareness about the disease and the new methods to detect Duchenne muscular dystrophy at an early stage to enable quick recovery by providing timely treatment. Duchenne muscular dystrophy is a genetic disorder that affects muscle growth, eventually leading to the deterioration of the heart, lung, and skeletal muscles. This disorder commonly occurs in males as the dystrophin gene is found in the X chromosome. Duchenne is the most common form of muscular dystrophy occurring in children aged between 2 and 6 years. It affects over 10000 males approximately at birth per year in the U.S.

No specific treatment is available for Duchenne muscular dystrophy but testing is an important aspect as quick measures are the key for recovery. The Duchenne muscular dystrophy testing market will particularly benefit from the factor of the need for quick diagnosis. The high cost of Duchenne muscular dystrophy testing depending on the complexity may hinder the growth of Duchenne muscular dystrophy testing market. Based on the type of tests, the Duchenne muscular dystrophy testing market can be segmented into a genetic test, electromyography test, and blood enzyme test.

Get Sample Copy of this Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6495

Varied Testing Methods Steering Duchenne Muscular Dystrophy Testing Market toward Growth

Manufacturers in the Duchenne muscular dystrophy testing market are expanding their footprint through research and development activities, which helps in developing novel Duchenne muscular dystrophy testing methods for effective diagnosis and treatment.

Recently, researchers came up with a new relative coupling coefficient that can be used for Duchenne muscular dystrophy testing. In this technique, the researchers used cost-effective inertial sensors and measured body movements of different body parts. Accelerometers were also placed on forearms, the core of the body, and leg flanks. To capture the data in the human gait, the researchers made use of the human gait pattern. These data-infused screening methodologies for Duchenne muscular dystrophy testing can prove to be a boon for the growth of the Duchenne muscular dystrophy testing market.

Considerable support from nonprofit health agencies is helping tackle the high cost of Duchenne muscular dystrophy testing. This factor may benefit the Duchenne muscular dystrophy testing market to a great extent. Invitae, a medical genetics company, recently partnered with the Muscular Dystrophy Association (MDA) for free genetic testing in the U.S. and Canada through Invitae’s Detect Muscular Dystrophy program. Such initiatives and campaigns can accelerate diagnosis and urge people to go for diagnosis.

Government Support Generating Growth for Duchenne Muscular Dystrophy Testing Market
Government support is also proving to be beneficial for the growth of the Duchenne muscular dystrophy testing market. The U.S. Food and Drug Administration (FDA) recently authorized Duchenne muscular dystrophy testing for newborn babies. The GSP Neonatal Creatine Kinase-MM kit will enable newborn screening to identify whether s/he has Duchenne muscular dystrophy. These developments trigger the growth of the Duchenne muscular dystrophy testing market.

Check Table of Contents of this Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6495


The Duchenne muscular dystrophy testing market is geographically spread across North America, the Middle East and Africa, Latin America, Europe, and Asia Pacific. North America is eyeing considerable growth in the Duchenne muscular dystrophy testing market due to the increasing number of Duchenne muscular dystrophy cases in the U.S. and a highly-developed healthcare system. Europe is also projected to show steady growth as the Duchenne muscular dystrophy cases are seeing an increase. An increase in the research and development activities coupled with stellar health infrastructure may further enhance the growth rate of the Duchenne muscular dystrophy testing market. Other regions may also observe moderate growth during the forecast period.